Research programme: therapeutic monoclonal antibodies - Merck/XOMA
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Schering-Plough; XOMA
- Developer XOMA
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA (Parenteral)
- 23 Mar 2010 Preclinical development is ongoing
- 17 Jan 2007 Schering-Plough exercises its right to additional discovery and development programmes with XOMA